Viking Therapeutics (VKTX) Profit After Tax (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Profit After Tax data on file, last reported at -$159.6 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 249.69% year-over-year to -$159.6 million; the trailing twelve-month figure through Mar 2026 stood at -$473.5 million (down 268.11% YoY), and the FY2025 full-year result was -$359.6 million, down 225.87% from the prior year.
• Profit After Tax slipped to -$159.6 million in Q1 2026, from -$157.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$15.8 million in Q3 2022 to a low of -$159.6 million in Q1 2026.
• A 5-year average of -$46.1 million and a median of -$24.6 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax dropped 10.29% in 2023 and slumped 340.2% in 2025, its largest moves.
• Tracing VKTX's Profit After Tax over 5 years: stood at -$18.3 million in 2022, then tumbled by 34.11% to -$24.6 million in 2023, then plunged by 45.56% to -$35.8 million in 2024, then plunged by 340.2% to -$157.7 million in 2025, then decreased by 1.2% to -$159.6 million in 2026.
• Business Quant data shows VKTX's Profit After Tax at -$159.6 million in Q1 2026, -$157.7 million in Q4 2025, and -$90.8 million in Q3 2025.